DFTX Definium Therapeutics, Inc. - Common Shares
NASDAQ · Visualizza su SEC EDGAR ↗ chiudi Ott 5, 2026 10-K/10-Q Ago 6, 2026DFTX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
DFTX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 29 Agosto 2022 | 1-for-15 | Inverso |
Informazioni su Definium Therapeutics, Inc. - Common Shares Panoramica della società da Wikipedia
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
History
MindMed was founded in May 2019 by Stephen Hurst and Jamon Rahn.
MindMed initially focused on developing treatments for opioid withdrawal and opioid use disorder with 18-MC, a non-hallucinogenic molecule based on the psychoactive alkaloid ibogaine. In June 2019, it acquired the 18-MC drug development program, previously funded by the National Institute on Drug Abuse, and in September began to prepare 18-MC for a Phase I FDA clinical trial to enable further clinical trials targeting opioid withdrawal and opioid use disorder.
MindMed was the first psychedelic pharmaceutical company to go public, listing on the Canadian NEO Exchange in March of 2020 through a reverse takeover with the Canadian gold mining company Broadway Gold Mining. It began trading on the Nasdaq as MNMD in April 2021 after being approved for an uplisting from the OTC Markets.
In a press release on June 9, 2021 MindMed announced that Jamon Rahn was stepping down both as the CEO and as a director on the board, to be replaced by then CDO Robert Barrow.
On February 26, 2021, MindMed closed its acquisition of digital health startup HealthMode. In connection with the acquisition, Daniel Karlin MD, CEO of HealthMode, was appointed to the position of CMO of the company.
On August 25, 2022, the first patient was dosed in a phase 2b trial for treatment of MM120 (now DT120) in generalized anxiety disorder (GAD). The study would go on to recruit 198 participants. The majority of trial participants experienced statistically significant improvements in their GAD scores, leading to the approval of multiple phase three human trials.
On January 12, 2026, MindMed rebranded to Definium Therapeutics.
Research
In March 2020, MindMed announced that it had partnered with NYU Langone to launch a clinical training program to train psychiatrists in psychedelic therapies and research to advance and deploy psychedelic medicines. The company committed $5 million to establish the center, which will also explore 18-MC and the use of drugs, including psilocybin-assisted therapy for alcohol use disorder.
In April 2020, the company entered into a long-term partnership with University Hospital Basel's Liechti Lab, gaining rights to more than ten years of the lab's data related to LSD, MDMA, and other psychedelic substances. The development of a novel compound designed to shorten the duration or stop an LSD experience that would allow LSD to be more widely used in a therapeutic environment was subsequently announced. Later that year a clinical trial studying the effects of DMT, the primary psychoactive ingredient in ayahuasca, and clinical trials combining MDMA and LSD were announced. A study to better understand and compare the altered states of consciousness induced by psilocybin and LSD began in August 2020,
and in October a Phase 1 study at the Liechti Lab on the acute dose dependent effects of LSD was completed. The results of the study were published by the American College of Neuropsychopharmacology in the journal Neuropsychopharmacology. In September 2021, further results were presented by Matthias Liechti, head of the Liechti Lab, at the INSIGHT Conference in Berlin. The results included the first clinical evidence on the comparative effects of LSD and psilocybin, stating 100mcg of LSD produced the same acute perceptual effects as a dose of 20 mg of psilocybin in healthy volunteers. Additionally, psilocybin taken after administering antidepressants for two weeks prior, was deemed safe, as well as reduced anxiety and blood pressure without hindering the psychedelic experience.
In December 2020, MindMed entered into an investigator-sponsored study agreement with Maastricht University in the Netherlands. The university provided facilities and personnel for a Phase 1 study to evaluate the effects of two low doses of LSD on mood, sleep and neuroplasticity.
In March 2024, the FDA granted breakthrough therapy designation to MindMed's form of LSD (MM120; now DT120) for the treatment of generalized anxiety disorder. This decision was influenced by a drug trial in which approximately half of the participants experienced significant relief from their symptoms. Positive results in clinical trials against general depression symptoms and generalized anxiety disorder were reported in 2026.
=== Ongoing clinical trials ===
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | DFTX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E | -18.1 | · | · | · | |
| P/S | 894.0 | · | · | · | |
| P/B (MRQ) | 5.5 | · | · | · | |
| EV / EBITDA | -19.9 | · | · | · | |
| Price / Cash Flow (Prezzo / Flusso di cassa) | -28.0 | · | · | · | |
| EV / Revenue (EV / Ricavi) | 803.9 | · | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 11.8 | · | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | DFTX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| ROA | -49.5%media 5 anni ≈-55.1% | ≈-55.1% | · | · | |
| ROE | -71.0%media 5 anni ≈-64.1% | ≈-64.1% | · | · | |
| ROIC | -44.6% | · | · | · |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | DFTX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | 0.0media 5 anni ≈0.1 | ≈0.1 | · | · | |
| Rapporto corrente (MRQ) | 6.9media 5 anni ≈7.6 | ≈7.6 | · | · | |
| Quick Ratio | 6.2media 5 anni ≈7.4 | ≈7.4 | · | · | |
| Debito a lungo termine / Patrimonio netto (MRQ) | 0.0media 5 anni ≈0.1 | ≈0.1 | · | · | |
| Interest Coverage (Copertura degli interessi) | -30.3 | · | · | · |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | DFTX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 212.0% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 6, 2026 | $-1.44 | $-0.56 | -158.2% |
| 31 Marzo 2026 | Mag 7, 2026 | $-0.71 | $-0.50 | -41.4% |
| 31 Dicembre 2025 | $-0.50 | $-0.50 | -0.52% | |
| 30 Settembre 2025 | $-0.78 | $-0.51 | -52.6% | |
| 30 Giugno 2025 | $-0.50 | $-0.37 | -34.5% | |
| 31 Marzo 2025 | $-0.27 | $-0.37 | 27.6% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $65M | $52M | $36M | $35M | $19M | |
| SG&A Expense | $49M | $39M | $42M | $30M | $59M | $14M | |
| Operating Expenses | $166M | $104M | $94M | $66M | $94M | $33M | |
| Operating Income | $-166M | $-104M | $-94M | $-66M | $-94M | $-33M | |
| Interest Expense | $5M | $2M | $920.0K | · | · | · | |
| Other Non-op | $-17M | $-5M | $-2M | $10M | $-339.0K | $-907.0K | |
| Pretax Income | $-184M | $-109M | $-96M | $-57M | $-94M | $-34M | |
| Income Tax | $0 | · | · | · | $-1M | · | |
| Net Income | $-184M | $-109M | $-96M | $-57M | $-93M | $-34M | |
| EPS (Basic) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| EPS (Diluted) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| Shares (Basic) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| Shares (Diluted) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| EBITDA | $-166M | $-104M | $-94M | $-66M | $-94M | · |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258M | $274M | $100M | $142M | $134M | $80M | |
| Short-term Investments | $154M | $0 | · | · | · | · | |
| Prepaid Expense | $8M | $8M | $4M | $4M | $4M | $1M | |
| Current Assets | $419M | $282M | $104M | $146M | $137M | $82M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $0 | |
| Intangibles | · | $0 | $527.0K | $4M | $7M | · | |
| Other Non-current Assets | $862.0K | $613.0K | $224.0K | $331.0K | · | · | |
| Total Assets | $440M | $302M | $125M | $170M | $164M | $82M | |
| Accounts Payable | $5M | $2M | $4M | $2M | $4M | $2M | |
| Accrued Liabilities | $20M | $13M | $12M | $6M | $6M | $986.0K | |
| Current Liabilities | $67M | $39M | $32M | $18M | $10M | $3M | |
| Other Non-current Liabilities | $496.0K | · | $32.0K | $1M | $2M | · | |
| Total Liabilities | $108M | $61M | $46M | $19M | $12M | $6M | |
| Total Debt | $41M | $22M | $14M | · | · | · | |
| Common Stock | · | · | $0 | · | · | · | |
| Retained Earnings | $-583M | $-399M | $-290M | $-194M | $-138M | $-45M | |
| AOCI | $1M | $819.0K | $343.0K | $627.0K | $1M | $284.0K | |
| Stockholders' Equity | $332M | $241M | $78M | $151M | $152M | $76M | |
| Liabilities + Equity | $440M | $302M | $125M | $170M | $164M | $82M | |
| Shares Outstanding | 98,776,265 | 75,100,763 | 41,101,303 | 37,979,136 | 28,126,414 | · |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Deferred Tax | · | · | · | · | $-1M | · | |
| Amort. of Intangibles | $0 | $527.0K | $3M | $3M | $3M | $0 | |
| Operating Cash Flow | $-132M | $-79M | $-64M | $-50M | $-46M | $-24M | |
| Investing Cash Flow | $-152M | $0 | · | · | $-297.0K | · | |
| Stock Issued | $0 | $984.0K | $8M | $42M | $82M | $72M | |
| Net Stock Activity | $0 | $984.0K | $8M | $42M | $82M | · | |
| Financing Cash Flow | $267M | $253M | $22M | $59M | $99M | $97M | |
| Net Change in Cash | $-16M | $174M | $-42M | $9M | $53M | $73M | |
| Taxes Paid | $0 | · | · | · | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| Net Margin | · | · | -2052.6% | -3799.1% | 25915.3% | · | |
| Pretax Margin | · | · | -2052.6% | -3799.1% | 26237.6% | · | |
| EBITDA Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| ROA | -49.5% | -50.9% | -65.0% | -34.0% | -75.8% | · | |
| ROE | -71.0% | -43.2% | -110.0% | -37.3% | -58.9% | · | |
| ROIC | -44.6% | · | · | · | -61.1% | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 | · | |
| Quick Ratio | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 | · | |
| Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| Interest Coverage | -30.3 | -45.5 | · | · | · | · |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | -0.0 | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.36 | $3.21 | $1.90 | $3.97 | · | · | |
| Revenue / Share | · | · | $0.12 | $0.05 | · | · | |
| Cash Flow / Share | $-1.47 | $-1.12 | $-1.64 | $-1.62 | · | · | |
| Cash / Share | $2.61 | $3.65 | $2.43 | $3.74 | · | · | |
| EPS (TTM) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 212.0% | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $4M | $5M | $1M | $-359.0K | · | |
| Net Income TTM | $-184M | $-109M | $-96M | $-57M | $-93M | · | |
| Market Cap | $1.32B | $523M | · | · | · | · | |
| Enterprise Value | $952M | $271M | · | · | · | · | |
| P/E | -6.5 | -4.5 | · | · | · | · | |
| P/S | 321.2 | 126.9 | · | · | · | · | |
| P/B | 4.0 | 2.2 | · | · | · | · | |
| P / Tangible Book | 4.2 | 2.4 | · | · | · | · | |
| P / Cash Flow | -10.1 | -6.6 | · | · | · | · | |
| EV / EBITDA | -5.7 | -2.6 | · | · | · | · | |
| EV / Revenue | 231.1 | 65.8 | · | · | · | · | |
| Earnings Yield | -15.4% | -22.1% | · | · | · | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $49M | $41M | $34M | $31M | $30M | $23M | $22M | $17M | $15M | $12M | $12M | $13M | $15M | $13M | $9M | $8M | |
| SG&A Expense | $26M | $18M | $14M | $15M | $11M | $9M | $11M | $8M | $10M | $10M | $11M | $8M | $14M | $8M | $5M | $9M | |
| Operating Expenses | $75M | $59M | $48M | $46M | $41M | $32M | $32M | $25M | $24M | $22M | $22M | $22M | $29M | $21M | $14M | $17M | |
| Operating Income | $-75M | $-59M | $-48M | $-46M | $-41M | $-32M | $-32M | $-25M | $-24M | $-22M | $-22M | $-22M | $-29M | $-21M | $-14M | $-17M | |
| Interest Expense | $1M | $1M | $1M | $1M | $2M | $602.0K | $656.0K | $727.0K | $466.0K | $434.0K | $439.0K | $328.0K | $77.0K | $76.0K | · | · | |
| Other Non-op | $-84M | $-18M | $-3M | $-22M | $-2M | $9M | $-2M | $11M | $19M | $-32M | $-2M | $4M | $54.0K | $-4M | $9M | $498.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-5M | $-16M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Net Income | $-159M | $-77M | $-50M | $-67M | $-43M | $-23M | $-35M | $-14M | $-6M | $-54M | $-24M | $-18M | $-29M | $-25M | $-5M | $-16M | |
| EPS (Basic) | $-1.44 | $-0.71 | $-0.51 | $-0.78 | $-0.50 | $-0.27 | $-0.14 | $-0.18 | $-0.08 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| EPS (Diluted) | $-1.44 | $-0.71 | $-0.43 | $-0.78 | $-0.50 | $-0.35 | $0.13 | $-0.27 | $-0.26 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| Shares (Basic) | 110,684,720 | 108,790,941 | · | 85,885,516 | 85,347,677 | 85,067,855 | · | 77,909,441 | 71,912,323 | 47,860,757 | · | 39,720,007 | 38,576,394 | 38,077,251 | · | 29,296,333 | |
| Shares (Diluted) | 110,684,720 | 108,790,941 | · | 85,885,516 | 85,347,677 | 87,091,461 | · | 80,238,688 | 75,304,101 | 47,860,757 | · | 39,720,007 | 38,576,394 | 38,077,251 | · | 29,296,333 | |
| EBITDA | $-75M | $-59M | · | $-46M | $-41M | $-32M | · | $-25M | $-24M | $-22M | · | $-22M | $-29M | $-21M | · | $-17M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $655M | $263M | $258M | $20M | $33M | $83M | $274M | $295M | $243M | $252M | $100M | $118M | $117M | $129M | $142M | $155M | |
| Short-term Investments | $429M | $111M | $154M | $189M | $150M | $130M | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $8M | $7M | $8M | $7M | $6M | $9M | $8M | $4M | $5M | $3M | $4M | $2M | $3M | $3M | $4M | $2M | |
| Current Assets | $1.09B | $381M | $419M | $216M | $189M | $222M | $282M | $299M | $248M | $255M | $104M | $120M | $120M | $132M | $146M | $157M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | $527.0K | $1M | $2M | $3M | $4M | $4M | |
| Other Non-current Assets | $880.0K | $812.0K | $862.0K | $1M | $1M | $606.0K | $613.0K | $493.0K | $534.0K | $144.0K | $224.0K | $229.0K | $268.0K | $300.0K | $331.0K | · | |
| Total Assets | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Accounts Payable | $7M | $7M | $5M | $8M | $4M | $2M | $2M | $2M | $3M | $8M | $4M | $8M | $9M | $2M | $2M | $824.0K | |
| Accrued Liabilities | $37M | $25M | $20M | $19M | $15M | $11M | $13M | $9M | $8M | $10M | $12M | $10M | $10M | $7M | $6M | $7M | |
| Current Liabilities | $157M | $81M | $67M | $65M | $38M | $30M | $39M | $33M | $42M | $65M | $32M | $31M | $35M | $24M | $18M | $26M | |
| Other Non-current Liabilities | $549.0K | $559.0K | $496.0K | $519.0K | $543.0K | · | · | · | · | $15.0K | $32.0K | $349.0K | $992.0K | $1M | $1M | $1M | |
| Total Liabilities | $194M | $122M | $108M | $106M | $80M | $53M | $61M | $58M | $66M | $79M | $46M | $46M | $36M | $25M | $19M | $27M | |
| Total Debt | $36M | $41M | · | $40M | $41M | $22M | · | $24M | $24M | $14M | · | $14M | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | $0 | $0 | · | $0 | · | · | · | · | · | |
| Retained Earnings | $-819M | $-660M | $-583M | $-532M | $-465M | $-422M | $-399M | $-364M | $-350M | $-345M | $-290M | $-266M | $-248M | $-219M | $-194M | $-190M | |
| AOCI | $417.0K | $824.0K | $1M | $1M | $807.0K | $802.0K | $819.0K | $821.0K | $833.0K | $836.0K | $343.0K | $777.0K | $362.0K | $641.0K | $627.0K | $743.0K | |
| Stockholders' Equity | $919M | $279M | $332M | $131M | $185M | $223M | $241M | $262M | $202M | $196M | $78M | $96M | $106M | $130M | $151M | $154M | |
| Liabilities + Equity | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Shares Outstanding | 134,365,950 | 104,044,508 | 98,776,265 | 76,774,057 | 75,803,251 | 75,511,375 | 75,100,763 | 81,590,491 | 72,075,076 | 71,163,720 | 41,101,303 | 40,094,708 | 38,807,159 | 38,290,111 | 37,979,136 | 37,541,115 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amort. of Intangibles | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $527.0K | $771.0K | $800.0K | $800.0K | $791.0K | $800.0K | $800.0K | |
| Operating Cash Flow | $-53M | $-43M | $-43M | $-30M | $-30M | $-29M | $-25M | $-17M | $-20M | $-17M | $-21M | $-17M | $-14M | $-13M | $-13M | $-9M | |
| Investing Cash Flow | $-317M | $42M | $35M | $15M | $-40M | $-162M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | $3M | $3M | $1M | $583.0K | $730.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $583.0K | · | · | |
| Financing Cash Flow | $762M | $5M | $246M | $749.0K | $20M | $1M | $4M | $69M | $11M | $169M | $3M | $17M | $1M | $583.0K | $416.0K | $58M | |
| Net Change in Cash | $393M | $5M | $238M | $-13M | $-49M | $-191M | $-22M | $52M | $-9M | $153M | $-18M | $804.0K | $-13M | $-13M | $-12M | $49M |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| Net Margin | · | · | · | · | · | · | · | · | · | · | · | -1541.1% | -2222.0% | -1932.6% | · | -4579.2% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -4579.2% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| ROA | -23.1% | -22.8% | · | -24.2% | -16.0% | -8.5% | · | -5.9% | -2.9% | -25.2% | · | -11.1% | -21.1% | -16.3% | · | -18.2% | |
| ROE | -28.8% | -30.7% | · | -34.2% | -22.1% | -11.2% | · | -7.6% | -3.8% | -33.3% | · | -14.4% | -25.3% | -18.6% | · | -21.5% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -11.1% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.9 | 4.7 | · | 3.3 | 5.0 | 7.3 | · | 9.0 | 5.9 | 3.9 | · | 3.9 | 3.4 | 5.5 | · | 6.0 | |
| Quick Ratio | 6.9 | 4.6 | · | 3.2 | 4.8 | 7.0 | · | 8.9 | 5.8 | 3.9 | · | 3.8 | 3.3 | 5.4 | · | 5.9 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| Interest Coverage | -60.9 | -47.6 | · | -35.8 | -17.5 | -53.4 | · | -34.1 | -52.5 | -51.2 | · | · | · | · | · | · |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.84 | $2.68 | · | $1.70 | $2.45 | $2.95 | · | $3.21 | $2.80 | $2.75 | · | $2.39 | $2.73 | $3.40 | · | $4.09 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | · | · | $0.03 | $0.03 | $0.03 | · | $0.01 | |
| Cash Flow / Share | · | $-0.39 | · | · | · | $-0.34 | · | · | · | $-0.35 | · | · | · | $-0.35 | · | · | |
| Cash / Share | $4.88 | $2.52 | · | $0.26 | $0.44 | $1.10 | · | $3.62 | $3.37 | $3.55 | · | $2.94 | $3.01 | $3.38 | · | $4.12 | |
| EPS (TTM) | $-3.36 | $-2.42 | · | $-1.50 | $-0.99 | $-0.75 | · | $-2.25 | $-2.43 | $-2.93 | · | $-1.88 | $-1.99 | $-1.83 | · | $-2.41 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $5M | · | $5M | $5M | $5M | · | $5M | $5M | $5M | · | $5M | $4M | $3M | · | $276.0K | |
| Net Income TTM | $-354M | $-238M | · | $-168M | $-115M | $-78M | · | $-98M | $-102M | $-125M | · | $-77M | $-75M | $-63M | · | $-69M | |
| Market Cap | $6.32B | $1.97B | · | $905M | $492M | $442M | · | $464M | $520M | $669M | · | · | · | · | · | · | |
| Enterprise Value | $5.27B | $1.63B | · | $736M | $350M | $251M | · | $193M | $301M | $431M | · | · | · | · | · | · | |
| P/E | -14.0 | -7.8 | · | -7.9 | -6.6 | -7.8 | · | -2.5 | -3.0 | -3.2 | · | · | · | · | · | · | |
| P/S | 1306.4 | 406.5 | · | 187.1 | 101.7 | 91.3 | · | 96.0 | 107.4 | 138.3 | · | · | · | · | · | · | |
| P/B | 6.9 | 7.1 | · | 6.9 | 2.7 | 2.0 | · | 1.8 | 2.6 | 3.4 | · | · | · | · | · | · | |
| P / Tangible Book | 7.0 | 7.6 | · | 8.2 | 3.0 | 2.2 | · | 1.9 | 2.9 | 3.8 | · | · | · | · | · | · | |
| P / Cash Flow | · | -46.1 | · | · | · | -15.0 | · | · | · | -40.3 | · | · | · | · | · | · | |
| EV / Revenue | 1089.9 | 337.7 | · | 152.2 | 72.4 | 52.0 | · | 39.9 | 62.2 | 89.0 | · | · | · | · | · | · | |
| Earnings Yield | -7.1% | -12.8% | · | -12.7% | -15.2% | -12.8% | · | -39.5% | -33.7% | -31.2% | · | · | · | · | · | · |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Margine Operativo % | · | · | -2012.6% | -4436.9% | 26143.2% |
| Utile netto | $-184M | $-109M | $-96M | $-57M | $-93M |
| EPS Diluito | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.1 | 0.1 | 0.2 | · | · |
| Rapporto corrente | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 |
| Quick Ratio | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 |
Dati fondamentali insufficienti per creare questo bilancio al momento.
Proprietari istituzionali (13F) 389 filer · $5.1B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 163 | 28 | 120 | 65 | · |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata. Variazione vs trimestre precedente non mostrata: la copertura dei dichiaranti differisce troppo tra questi due trimestri per un confronto affidabile.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $528.392.511 | 11.232.834 | 10,30% | Azioni |
| Avoro Capital Advisors LLC | $338.165.292 | 7.188.888 | 6,59% | Azioni |
| Driehaus Capital Management LLC | $322.001.783 | 6.845.276 | 6,28% | Azioni |
| Capital World Investors | $252.497.690 | 5.367.723 | 4,92% | Azioni |
| FMR LLC | $223.577.402 | 4.752.921 | 4,36% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $171.482.802 | 3.644.813 | 3,34% | Azioni |
| STATE STREET CORP | $144.195.946 | 3.065.390 | 2,81% | Azioni |
| Capital International Investors | $139.398.806 | 2.963.410 | 2,72% | Azioni |
| Octagon Capital Advisors LP | $138.768.000 | 2.950.000 | 2,71% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $138.755.487 | 2.949.734 | 2,71% | Azioni |
| Deep Track Capital, LP | $129.360.000 | 2.750.000 | 2,52% | Azioni |
| Commodore Capital LP | $94.080.000 | 2.000.000 | 1,83% | Azioni |
| GOLDMAN SACHS GROUP INC | $84.712.079 | 1.800.852 | 1,65% | Azioni |
| CITADEL ADVISORS LLC | $79.431.133 | 1.688.587 | 1,55% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $77.541.959 | 1.648.426 | 1,51% | Azioni |
| RA CAPITAL MANAGEMENT, L.P. | $70.560.000 | 1.500.000 | 1,38% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $69.922.796 | 1.486.454 | 1,36% | Azioni |
| JANUS HENDERSON GROUP PLC | $67.226.955 | 3.556.041 | 1,31% | Azioni |
| Siren, L.L.C. | $66.772.951 | 1.419.493 | 1,30% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65.216.256 | 1.386.400 | 1,27% | Opzione Call |
| MARSHALL WACE, LLP | $61.102.420 | 1.298.946 | 1,19% | Azioni |
| NORTHERN TRUST CORP | $55.000.956 | 1.169.238 | 1,07% | Azioni |
| AMERIPRISE FINANCIAL INC | $54.018.997 | 1.148.363 | 1,05% | Azioni |
| Nuveen, LLC | $51.993.971 | 1.105.314 | 1,01% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $50.971.415 | 1.083.576 | 0,99% | Azioni |
| Woodline Partners LP | $47.211.273 | 1.003.641 | 0,92% | Azioni |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $47.040.000 | 1.000.000 | 0,92% | Azioni |
| Boxer Capital Management, LLC | $46.969.440 | 998.500 | 0,92% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $43.362.319 | 921.818 | 0,85% | Azioni |
| Balyasny Asset Management L.P. | $42.217.365 | 897.478 | 0,82% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $38.934.679 | 827.693 | 0,76% | Azioni |
| Holocene Advisors, LP | $37.470.841 | 796.574 | 0,73% | Azioni |
| AWM Investment Company, Inc. | $36.916.992 | 784.800 | 0,72% | Azioni |
| Bank of New York Mellon Corp | $36.562.821 | 777.271 | 0,71% | Azioni |
| Polar Capital Holdings Plc | $36.561.981 | 777.253 | 0,71% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $34.082.124 | 1.803.287 | 0,66% | Azioni |
| EVENTIDE ASSET MANAGEMENT, LLC | $33.398.400 | 710.000 | 0,65% | Azioni |
| NEUBERGER BERMAN GROUP LLC | $32.341.834 | 687.539 | 0,63% | Azioni |
| Qube Research & Technologies Ltd | $32.123.663 | 682.901 | 0,63% | Azioni |
| Candriam S.C.A. | $28.874.744 | 614.425 | 0,56% | Azioni |
| ArrowMark Colorado Holdings LLC | $26.533.806 | 564.069 | 0,52% | Azioni |
| Catalio Capital Management, LP | $26.468.091 | 562.672 | 0,52% | Azioni |
| Blackstone Inc. | $26.418.228 | 561.612 | 0,52% | Azioni |
| Integral Health Asset Management, LLC | $25.872.000 | 550.000 | 0,50% | Azioni |
| BAMCO INC /NY/ | $24.465.880 | 520.108 | 0,48% | Azioni |
| UBS Group AG | $23.494.928 | 499.467 | 0,46% | Azioni |
| FRANKLIN RESOURCES INC | $22.871.742 | 486.219 | 0,45% | Azioni |
| Point72 Asset Management, L.P. | $22.766.419 | 483.980 | 0,44% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22.155.840 | 471.000 | 0,43% | Opzione Put |
| Ensign Peak Advisors, Inc | $21.925.626 | 466.106 | 0,43% | Azioni |
Insider aziendali 16 insider · 9 dirigenti · 9 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Robert Barrow | Chief Executive Officer | 25 Settembre 2026 S | 2.213.090 | 0 | 5 | $-3.981.146 |
| Brandi Roberts | Chief Financial Officer | 25 Settembre 2026 S | 394.528 | 0 | 2 | $-259.172 |
| Schond L. Greenway | Chief Financial Officer | 25 Marzo 2024 F | 211.057 | 0 | 0 | $0 |
| Miri Halperin Wernli | Executive President | 21 Agosto 2024 M | 202.405 | 0 | 0 | $0 |
| Dan Karlin | Chief Medical Officer | 25 Settembre 2026 S | 792.846 | 0 | 4 | $-1.070.502 |
| Matthew T. Wiley | Chief Commercial Officer | 25 Settembre 2026 S | 359.036 | 0 | 2 | $-242.358 |
| Mark Sullivan | Chief Legal Officer | 25 Settembre 2026 S | 494.228 | 0 | 4 | $-1.445.540 |
| Carrie Liao | Chief Accounting Officer | 25 Marzo 2025 S | 144.923 | 0 | 0 | $0 |
| Cynthia W. Hu | Chief Legal Officer&Secretary | 24 Marzo 2022 A | 1.200.000 | 0 | 0 | $0 |
| Andreas Krebs | Direttore | 18 Settembre 2026 M | 21.402 | 0 | 0 | $0 |
| Carol A Vallone | Direttore | 18 Settembre 2026 M | 22.296 | 0 | 0 | $0 |
| Roger Adsett | Direttore | 11 Giugno 2026 A | 3.555 | 0 | 0 | $0 |
| Roger Crystal | Direttore | 11 Giugno 2026 A | 24.289 | 0 | 0 | $0 |
| Suzanne Louise Bruhn | Direttore | 11 Giugno 2026 A | 24.289 | 0 | 0 | $0 |
| David W Gryska | Direttore | 11 Giugno 2026 A | 19.900 | 0 | 0 | $0 |
| Brigid Makes | Direttore | 01 Giugno 2022 A | 158.706 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 22 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 2,13% | 10.109 NS | 31 Luglio 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,18% | 12.558 NS | 31 Luglio 2026 | N-PORT |
| IHE · iShares Trust | 1,12% | 479.902 SH | 11 Settembre 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,36% | 139.235 SH | 19 Agosto 2026 | Giornaliero |
| IBB · iShares Trust | 0,36% | 974.814 SH | 11 Settembre 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,34% | 9.504 SH | 02 Ottobre 2026 | Giornaliero |
| IWO · iShares Trust | 0,32% | 1.221.670 SH | 11 Settembre 2026 | Giornaliero |
| NUSC · Nushares ETF Trust | 0,31% | 90.473 NS | 31 Luglio 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,20% | 86.461 SH | 19 Agosto 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,19% | 748.959 SH | 19 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,18% | 62.307 NS | 31 Luglio 2026 | N-PORT |
| IWM · iShares Trust | 0,16% | 3.329.545 SH | 11 Settembre 2026 | Giornaliero |
| ESML · iShares Trust | 0,10% | 73.991 SH | 11 Settembre 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,08% | 331.180 SH | 19 Agosto 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,07% | 1.486.454 SH | 19 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 52.257 NS | 31 Luglio 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,06% | 103.206 NS | 31 Luglio 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 6.834 SH | 11 Settembre 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 17.940 SH | 02 Ottobre 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 10.703 SH | 19 Agosto 2026 | Giornaliero |
| IWV · iShares Trust | 0,01% | 34.866 SH | 10 Settembre 2026 | Giornaliero |
| ITOT · iShares Trust | 0,01% | 161.931 SH | 11 Settembre 2026 | Giornaliero |
DFTX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
Target Price a 12 Mesi
17 analisti · 2026-10-04Target medio $71.65 +92,2%
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| DFTX | $1.32B | -6.5 | 212.0% | · | -71.0% | · |
| AMRX | · | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| BLTE | $6.29B | -69.2 | · | · | -16.9% | · |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | · |
| MANE | · | · | · | · | 82.6% | · |
| EWTX | $2.64B | -15.2 | · | · | -30.2% | · |
| INDV | · | 21.9 | 4.3% | 17.0% | -118.3% | 80.2% |
| OGN | $1.87B | 10.0 | -2.9% | 3.0% | 25.2% | 53.3% |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | · |
| AMLX | $1.33B | -7.9 | -77.1% | · | -61.2% | · |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.